Received: 17 April 2020
Revised: 29 April 2020
Accepted: 22 May 2020
First Online: 30 May 2020
Change Date: 10 July 2020
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/S41375-020-0970-2
Compliance with ethical standards
: FHH: research funding: Novartis, Celgene, CTI; consultant for Novartis, Celgene, AOP and CTI. AH: research support: Novartis, BMS, Pfizer, Incyte. PJJ: advisory role, received honoraria, research funding, and/or travel/accommodation expenses from: Abbvie, Incyte, Bayer, Boehringer, Novartis, Pfizer, Servier, BMS and Celgene. MvLT: research funding: Celgene, Novartis, Gilead; honoraria and consultancy: Celgene, Janssen, Medac, Gilead, BMS, Oncopeptides, Takeda.
: The questionnaire and study protocol were approved by the Ethics Committee of the Jena University Hospital (Protocol #2018-1198-Reg).
Free to read: This content has been made available to all.